Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00268216
Status:
COMPLETED
Last Update Posted:
2017-01-20
First Post:
2005-12-20
Brief Title:
Survival Of Subjects With Chronic Obstructive Pulmonary Disease COPD
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Multicentre Randomised Double-blind Parallel Group Placebo-controlled Study to Investigate the Long-term Effects of SalmeterolFluticasone Propionate Seretide tm 50500mcg BD Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD All Delivered Via the Diskus tmAccuhaler tm Inhaler on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease COPD Over 3 Years of Treatment
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if fluticasone 500mcgsalmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug
Detailed Description:
A multicenter randomized double-blind parallel group placebo controlled study to investigate the effects of salmeterolfluticasone 50500mcg bd salmeterol 50mcg bd and fluticasone 500mcg bd all delivered via the DISKUSACCUHALER inhaler on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None